| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $10.7M | -12.6% | -24.2% |
| SG&A Expense | $4.5M | -7.6% | -3.3% |
| Operating Income | -$15.1M | +11.2% | +19.1% |
| Net Income | -$13.9M | +11.5% | +15.9% |
| EPS (Basic) | -$0.62 | +11.4% | +16.2% |
| EPS (Diluted) | -$0.62 | +11.4% | +16.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.0M | +1.9% | -62.7% |
| Short-term Investments | $102.6M | -8.8% | -19.2% |
| Current Assets | $120.2M | -7.4% | -29.5% |
| Total Assets | $168.7M | -6.0% | -3.6% |
| Current Liabilities | $11.8M | +28.6% | +18.3% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$36.6M | — | — |
| Capital Expenditures | $122K | — | — |
| Investing Cash Flow | $24.8M | — | — |
| Financing Cash Flow | $117K | — | — |
| Free Cash Flow | -$36.7M | — | — |
| $58.6M |
| +3.2% |
| — |
| Stockholders' Equity | $110.2M | -10.2% | -33.3% |